• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

After review of patient deaths, European regulators OK Actelion’s Uptravi

April 7, 2017 By Sarah Faulkner

After review of patient deaths, European regulators OK Actelion's UptraviThe European Medicines Agency told doctors today that they can continue to prescribe Actelion‘s (VTX:ATLN) pulmonary arterial hypertension drug, Uptravi. The regulatory body initiated a safety review in January after 5 patients in France died and docs were asked to stop prescribing the drug.

Regulators reported that their review did not suggest an increase in mortality linked to Uptravi. The drug is Actelion’s 3rd best-seller, accounting for nearly 10% of the company’s 2016 sales.

“No changes to the prescribing information are considered necessary,” said the agency, according to Reuters.

The news is likely reassuring to Johnson & Johnson (NYSE:JNJ), since the U.S. healthcare giant is in the middle of a $30 billion takeover of Actelion. The takeover is on track to close in the 2nd quarter.

Also this week, Actelion shareholders approved spinning off the company’s early clinical assets and drug discovery branch into a new company.

The newly formed biopharmaceutical company will be called Idorsia Ltd and will be led by Actelion CEO Jean-Paul Clozel. Shares in Idorsia are expected to list on the SIX Swiss Exchange on the day that Johnson & Johnson’s tender offer closes.

J&J will initially hold 16% of Idorsia shares, the U.S. healthcare giant said. It plans to de-list Actelion.

Last month, Johnson & Johnson said that it controls nearly 78% of voting rights in its acquisition of Actelion. Janssen, J&J’s Swiss subsidiary, declared the tender offer successful.

J&J will have 10 more trading days, between April 6 and April 21, for the subsequent acceptance of the tender offer, according to the company.

Filed Under: Featured, Mergers & Acquisitions, Regulatory/Compliance, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS